This single-center, randomized, controlled, single-blind clinical trial evaluates whether a stellate ganglion block (SGB) using bupivacaine can improve persistent symptoms in adults with long COVID. Participants are assigned in a 1:1 ratio to receive either an ultrasound-guided right-sided SGB or a placebo saline injection delivered to the sternocleidomastoid muscle.
View on ClinicalTrials.gov ↗Last updated 07 October 2026 from ClinicalTrials.gov. Trial statuses are refreshed automatically; check the registry record for the latest status and contact details.
5 trials2 open to enrolment2 completed1 unknown status
All interventional trials in our ClinicalTrials.gov extract that list Stellate Ganglion Block as an intervention, across Unspecified / Overlap (3), Long COVID / PASC (2). 2 are currently open to enrolment and 2 have completed. Read the OSMF evidence profile for Stellate Ganglion Block for literature, mechanism and dosing context.
Intervention names are normalised from the registry's own arm labels, so the same compound can appear under a brand name, a generic name or a combination; check the full agent index for related entries.
⚠️
Not medical advice. This page is an automatically compiled index of entries on ClinicalTrials.gov. Listing here is not an endorsement of any trial, sponsor or treatment, and trial status can change between our refreshes. Always confirm details on ClinicalTrials.gov and discuss participation with your own clinician.
Recruiting (1)
Not yet recruiting (1)
This single-center study aims to evaluate both immediate and long-term outcomes of stellate ganglion block (SGB) in a cohort of rigorously phenotyped patients with Postural Tachycardia Syndrome (POTS). By assessing the effects of SGB, this study seeks to determine its viability as an intervention for symptom control in POTS.
View on ClinicalTrials.gov ↗Completed (2)
Chronic olfactory dysfunction from the COVID-19 pandemic is a growing public health crisis with up to 1.2 million people in the Unites States affected. Olfactory dysfunction impacts one's quality of life significantly by decreasing the enjoyment of foods, creating environmental safety concerns, and affecting one's ability to perform certain jobs.
View on ClinicalTrials.gov ↗Chronic olfactory dysfunction, both hyposmia and parosmia, from the COVID-19 pandemic is a growing public health crisis with up to 1.2 million people in the United States affected. Olfactory dysfunction impacts one's quality of life significantly by decreasing the enjoyment of foods, creating environmental safety concerns, and affecting one's ability to perform certain jobs.
View on ClinicalTrials.gov ↗Unknown status (1)
Chronic olfactory dysfunction, both hyposmia and parosmia, from the COVID-19 pandemic is a growing public health crisis, affecting up to 1.2 million people in the United States. Olfactory dysfunction significantly impacts one's quality of life by decreasing the enjoyment of foods, creating environmental safety concerns, and affecting one's ability to perform specific jobs.
View on ClinicalTrials.gov ↗Frequently asked questions
How do I join a clinical trial?
Open the trial's ClinicalTrials.gov record (the "View on ClinicalTrials.gov" button), read the Eligibility Criteria and Contacts and Locations sections, and contact the study team listed there. Trials only enrol at the sites shown in the record, so check whether a site is near you or whether the study is remote/decentralised. Your own clinician can help you judge whether a trial is a sensible option and may need to provide medical records.
What do the trial phases mean?
Early Phase 1 / Phase 1 studies test safety and dosing in a small group. Phase 2 studies look for a signal of benefit in a larger group and keep checking safety. Phase 3 studies are large confirmatory trials designed to show whether a treatment works well enough for approval. Phase 4 studies follow approved treatments after they reach the market. "Phase not applicable" is used by the registry for behavioural, device, rehabilitation and other non-drug interventions.
Does the Open Source Medicine Foundation run these trials?
No. OSMF does not sponsor, run or recruit for any trial on this page. We compile public registry entries from ClinicalTrials.gov so patients and clinicians can find them in one place. For questions about a specific study, contact the sponsor or study team listed on its ClinicalTrials.gov record.
Get new recruiting trials in your inbox.
We summarise newly registered post-viral trials and notable results on the OSMF Substack.
Subscribe on SubstackCite this page
Open Source Medicine Foundation. Stellate Ganglion Block clinical trials for Long COVID, ME/CFS and post-viral illness (5 trials, updated October 2026). Research Tracker, 07 October 2026.
Underlying dataset (JSON, CC BY 4.0):
Open Source Medicine Foundation. Stellate Ganglion Block clinical trials for Long COVID, ME/CFS and post-viral illness (5 trials, updated October 2026). Research Tracker, 07 October 2026.
https://research.opensourcemed.info/trials/by-agent/stellate-ganglion-block.htmlUnderlying dataset (JSON, CC BY 4.0):
https://research.opensourcemed.info/data/clinical_trials/clinical_trials_current.json. Source records: ClinicalTrials.gov.Related: all agents · recruiting Long COVID trials · recruiting ME/CFS trials · open in trial finder.